Real-world safety of first-line enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: evidence from VigiBase and FAERS

BackgroundCompared with platinum-based chemotherapy, the combination of enfortumab vedotin and pembrolizumab (EV + Pembro) achieves higher durable response rates and improves survival outcomes in patients with locally advanced or metastatic urothelial carcinoma. As the first regimen pairing an immun...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Zuan Li, Han Qu, Shuowen Wang, Zizhen Liu, Zhenghua Wu, Shanshan Hu, Runjuan Yang, Qiying Yan, Dongying Wu, Yuefen Lou, Guorong Fan
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2026-06-01
Serie:	Frontiers in Immunology
Soggetti:	adverse drug events disproportionality analysis enfortumab vedotin FAERS pembrolizumab time to onset
Accesso online:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1759135/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!